Successful Treatment of Insulin Allergy with Desensitization Therapy: A Case Report and Literature Review

Hamza Elfekih, Faten Hadjkacem, Mouna Elleuch, Dorra Ghorbel, Nadia Charfi, Fatma Mnif, Nabila Rekik, Mouna Mnif, and Mohamed Abid

Department of Endocrinology and Diabetology, Hedi Chaker University Hospital, Sfax, Tunisia

ABSTRACT

Insulin therapy is an essential treatment for type 1 and uncontrolled type 2 diabetes mellitus (DM). Hypersensitivity reactions have been described since the first administration of insulin, the same as any other therapy. Despite being a rare situation nowadays, it requires careful intra-hospital monitoring and multidisciplinary management. Here, we present a case of a 57-year-old patient with type 2 DM, an average glycemic control, and both penicillin and insulin allergy. He underwent a desensitization protocol which allowed successfully dismiss him with intermediate-acting insulin.

Keywords: Desensitization, Immunologic; Diabetes mellitus; Hypersensitivity; Insulin

INTRODUCTION

Type 2 diabetes mellitus (DM) is a chronic disease characterized by a combination of reduced insulin secretion by pancreatic beta cells and a peripheral insulin resistance. The use of insulin therapy in type 2 DM is a part of the natural history of the disease.\(^1\)

Insulin is known to have several side effects including hypersensitivity reactions. In 1922, the first usage of insulin extracted from animal islet cells caused a callus at the injection site.\(^2\) After the introduction of the highly-purified animal insulin in the 1970s and Human insulin in 1978, the hypersensitivity reactions dramatically decreased from 50% in 1950 to less than 3% in 1990.\(^3\) Currently, the incidence is estimated at <1% to 2.4%.\(^4\)

Both, insulin and the additives in insulin preparations could cause hypersensitivity reactions ranging from minor local symptoms to severe anaphylaxis reactions.

Here, we report a case of insulin allergy that was successfully desensitized using NPH (neutral protamine Hagedorn)-based protocol, in addition to reviewing case reports found in Pubmed from 1997 to July 2017 using the following terms: "Hypersensitivity, Immediate"[Mesh] AND "Insulin"[Mesh] AND (Case Reports[ptyp] AND "humans"[MeSH Terms]) and the ones reported by S. Hasani-Ranjbar et al.\(^5\)

CASE REPORTS

A 57-year-old man with T2DM was referred to our Endocrinology Diabetology Department due to hypersensitivity manifestations that appeared a few minutes after each insulin injection.
The patient had an only significant history of allergy to penicillin. In his familial history, we found several members with Type 2 DM (T2DM), hypertension, early atherosclerotic cardiovascular disease and autoimmune diseases including Type 1 DM and hypothyroidism.

His diabetes was discovered 20 years ago, treated for two days by insulin then he was dismissed with oral anti-diabetic medication (OAD).

The patient was undergoing an irregular follow-up with poor glycemic control and HbA1c between 11.6% - 14% during the last few years. In order to achieve better glycemic control, the insulin therapy was initiated two years ago and the patient received subcutaneous injections of 10 IU bed-time of NPH insulin (Insulatard, strength: 100 IU/mL, Novo Nordisk, Bagsvaerd, Denmark) in addition to metformin 850 mg twice a day (b.i.d) and glimepiride 4 mg once a day (o.d).

The NPH was taken irregularly due to generalized pruritus and papular lesion located at the insulin injection site that was described since the first usage. The symptoms started ten minutes after the injection and disappear after a few hours. The same manifestations recurred after each injection. Few weeks before his admission, He received a 10 IU bed-time of biphasic insulin aspart (Novomix30 FlexPen, 100 IU/mL, Novo Nordisk, Bagsvaerd, Denmark) without significant improvement.

The admission exam in October 2016 found a patient with 181 cm Height, 76 kg weight, 95 cm waist size, a body mass index of 23 kg/m2 and a newly discovered hypertension treated by an Angiotensin-converting enzyme (ACE) inhibitor (Captopril 25 mg t.i.d). Diabetes autoantibodies were negative including Anti-GAD, anti-IA2, and anti-ICA antibodies. The biochemical evaluation revealed TSH and FT4 values in the normal references range 1.58 mIU/L and 15 [12-22 pmol/L] respectively and an elevated total Ig E dosage at 173 IU/ml [normal value < 150 IU/mL].

The treatment was switched to glargine (Lantus SoloStar, 100 IU/mL, Sanofi, Frankfurt, Germany) and the patient received 8 IU without premedication. A papule appeared ten minutes after the injection and disappearred after fifteen minutes without pruritus. The patient received after that H1 antagonist (cetirizine 10 mg q.d.) during 4 days followed by an injection of rapid-acting insulin (Jusline R, 100 IU/mL, Juphar, Ras Al Khaimah, U.A.E) that caused also a papular lesion without pruritus.

Since the patient presented hypersensitivity to different insulin preparations a desensitization protocol was planned after three months. The patient was dismissed with a satisfying glycemic control using glimepiride 2 mg o.d and metformin 850 mg b.i.d in addition to lifestyle management with fasting plasma glucose equal to 118 mg/dL and postprandial plasma glucose under 186 mg/dL.

In February 2017, during the second admission, the patient showed a suboptimal glycemic control with HbA1c equal to 7.7% and a stable weight. We tried first glulisine (Apidra Solostar, 100 UI/mL, Sanofi, Frankfurt, Germany) which contains essentially metacresol in addition to insulin which was stopped after the third injection since a papular lesion occurred again (Figures 1 and 2).

Due to the unavailability of specific IgE assay and skin tests, we tried to eliminate differential diagnosis especially dermographism and allergy to the components of the syringe. Applying pressure and friction to the skin, changing the needle, the injection site, verifying the injection procedure and injecting subcutaneously isotonic saline using the insulin syringe did not induce any allergic symptoms. We also tried to eliminate a possible metacresol allergy by giving subcutaneous injections of Test Medium FlexPen (Novo Nordisk, Bagsvaerd, Denmark) which does not show any allergic manifestation.

The patient underwent after that a desensitization protocol using progressive doses of NPH (Jusline N, 100 IU/mL, Julphar, Ras Al Khaimah, UAE) which contains essentially metacresol in addition to insulin, associated with an H1 antagonist (cetirizine 10 mg q.d.) and corticosteroid (Table 1).

He did not present any hypersensitization symptoms during this procedure even after stopping the premedication. He was dismissed with NPH 10 IU twice a day. Eight months after the desensitization, we obtained a satisfying glycemic control without recurrence of insulin allergy symptoms.
Figure 1. A papular lesion appearing 10 minutes after the third injection of glulisine in a 57-year-old patient with diabetes mellitus type 2

Figure 2. The papular lesion starting to fade after 1 hour and 30 minutes of the third injection of glulisine in a 57-year-old patient with diabetes mellitus type 2

Table 1. Desensitization protocol using neutral protamine Hagedorn (NPH) insulin in a 57-year-old patient with diabetes mellitus type 2 and insulin allergy

| Day | Time   | Premedication       | Insulin dose (IU) |
|-----|--------|---------------------|------------------|
| 1   | -30 min| H1 + 60 mg prednisone | 0.001            |
|     | 0      |                     |                  |
|     | 20 min |                     | 0.01             |
|     | 40 min |                     | 0.1              |
|     | 60 min |                     | 1                |
|     | 80 min |                     | 2                |
| 2   | -30 min| H1 + 30 mg prednisone | 0.1             |
|     | 0      |                     |                  |
|     | 20 min |                     | 1                |
|     | 40 min |                     | 2                |
|     | 60 min |                     | 3                |
| 3   | -30 min| H1 + 30 mg prednisone | 2               |
|     | 0      |                     |                  |
|     | 20 min |                     | 3                |
|     | 40 min |                     | 4                |
| 4   | -30 min| H1 (+ stop prednisone) | 5               |
|     | 0      |                     |                  |
|     | 20 min |                     | 6                |
| 5   | -30 min| H1                  | 6                |
|     | 0      |                     |                  |
|     | 20 min |                     | 8                |
| 6   | -30 min| H1                  | 6                |
|     | 8 AM   |                     |                  |
|     | 8 PM   |                     | 8                |
| 7   | -30 min| H1                  | 8                |
|     | 8 AM   |                     |                  |
|     | 8 PM   |                     | 10               |
| 8   | 8 AM   | (Stop H1)           | 10               |
|     | 8 PM   |                     |                  |
DISCUSSION

Insulin allergy is a rare condition that could be related to the components of insulin preparations mainly protamine,\textsuperscript{2} zinc\textsuperscript{6,7} and metacresol\textsuperscript{4,8,9} or in less than one-third of cases related to insulin itself.\textsuperscript{5} Its incidence dropped significantly after the introduction of the highly-purified animal insulin and the use of recombinant human insulin.\textsuperscript{3}

The manifestations may be type I IgE-mediated hypersensitivity, type III immune complex-mediated hypersensitivity or type IV delayed hypersensitivity. The reactions can vary from simple local reactions to a life-threatening anaphylactic reaction.\textsuperscript{10}

In order to confirm insulin allergy, the differential diagnosis should be excluded mainly skin diseases and an incorrect injection technique. U. Bodtger found that 59\% of suspected cases did not have an allergic cause.\textsuperscript{11}

In our case, the patient presented a type 1 IgE-mediated hypersensitivity with local, general manifestations and a high total IgE value. The dermatologic disease was eliminated, the injection technique was correct, the injection of isotonic saline solution using insulin syringe did not show any reaction eliminating a possible allergy to its components such as latex. The patient had a known history of allergy to penicillin which is reported to have a high prevalence in patients with insulin allergy.\textsuperscript{12}

Hypersensitivity reactions occur usually a few weeks, months or years after the onset of insulin therapy.\textsuperscript{13} In our case, it happened since the first injection which could be explained by his previous exposure to insulin.

We tried glargine since the insulin allergy was less frequent with insulin analogs, also glargine could be used as a desensitization treatment,\textsuperscript{5} however, the dose delivered to the patient was higher than the one required to start desensitization.

The patient presented hypersensitization to multiple insulin preparations including NPH, soluble insulin, biphasic insulin aspart, glargine, glulisine. The only common components existing in these preparations that were reported to cause allergy are metacresol and insulin (Table 2).\textsuperscript{3}

Allergy to metacresol was reported previously in the literature, and in order to eliminate a possible metacresol allergy, we used Test Medium FlexPen which contains metacresol and phenol without insulin. This procedure was used previously by B.J. Wheeler to prove the metacresol allergy.\textsuperscript{4}

Since the insulin allergy was confirmed and considering the patient age, the natural history of type 2 DM and the suboptimal glycemic control, we decided after the patient agreement to realize a desensitization protocol, similar to the one used by Rojas J,\textsuperscript{10} which was successful.

| Brand Name          | Insulin                  | Protamine | Zinc | Metacresol |
|---------------------|--------------------------|-----------|------|------------|
| Actrapid® human     | human Insulin rDNA       | X         | X    |            |
| Insuman rapid®      | human Insulin rDNA       | X         |      |            |
| Jusline R®          |                          |           |      |            |
| Insulatard®         | human Insulin rDNA       | X         | X    | X          |
| Insuman basal®      |                          |           |      |            |
| Jusline N®          |                          |           |      |            |
| Mixtard 30/70®      | human Insulin rDNA       | X         | X    | X          |
| Insuman comb30/70®  |                          | X         | X    | X          |
| Jusline 30:70®      |                          |           |      |            |
| Novomix 30®         | biphasic insulin asparte | X         | X    | X          |
| Novorapid flexpen®  | asparte                  | X         | X    |            |
| Apidra solostar®    | glulisine                 | X         |      |            |
| Levemir flexpen®    | detemir                   | X         |      |            |
| Lantus solostar®    | glargine                  | X         |      |            |

rDNA: recombinant DNA
The patient was allowed to receive metformin but glimepiride was prescribed only during the first four days considering the high dose of Prednisone. Although corticosteroids were used in desensitization protocols mainly when general symptoms were present, some authors used it concomitantly with insulin in local manifestations.\textsuperscript{14}

We found from 1997 to July 2017, 33 similar cases with immediate hypersensitivity reactions to different insulin types with a sex ratio of 1.06, 66.7% (n=22) type 2 DM patients, 24.2% (n=8) type 1 DM and 3 specific DM. The management of insulin allergy varied from interrupting the insulin therapy and resuming the OAD medications, keeping the same treatment or the same class and adding H1 antagonist, trying the type of insulin that showed the least reaction in the skin tests or using a desensitization protocol. The desensitization was done in 57.6% of cases (n=19) and a recurrence of symptoms was seen in 15.8% of cases only (n=3).

In case of unsuccessful desensitization, other options could be used including systemic steroids, immunosuppressive agents such as azathioprine, mycophenolate mofetil, and methotrexate, targeted biologic agents such as rituximab and omalizumab or even pancreas transplantation in case of generalized insulin allergy\textsuperscript{15-45} (Table 3).

| Author/Reference | Year | Age (years) | Sex | Type of DM | Duration of DM | Type of Insulin | Desensitization | Treatment | Results | Duration of follow-up | Recurrence | Other hypersensitivity agents |
|------------------|------|-------------|-----|------------|---------------|----------------|-----------------|-----------|--------|----------------------|------------|--------------------------|
| Belhekar M.N. (15) | 2015 | 41          | Female | 2         | 2 years       | Soluble insulin & NPH | No | glargine | No reaction | - | No penicillin and pentoxifylline |
| Pitrola D. (16)   | 2014 | 48          | Male | 2         | -             | Biphasic insulin lispro, biphasic insulin aspart & glargine | No | Stopped statin and ACE inhibitor and reintroduced glargine after 9 months | No reaction | 6 weeks | 2 |
| Jacquier J. (17)  | 2013 | 65          | Male | secondary to total pancreatectomy | 1.5 years | NPH & lispro | No | detemir, lispro & H1 antagonist | No reaction | 4 weeks | 2 | No |
| Jacquier J. (17)  | 2013 | 40          | Female | 1         | 4 months | glargine, lispro, detemir & aspart | No | aspart/continuous subcutaneous insulin infusion & H1 antagonist | Mild symptoms | 3 weeks | 2 | Animal dander, pollen, family history of atopy |
| Jacquier J. (17)  | 2013 | 40          | Female | 2         | 19 years | Soluble insulin & NPH | No | Insulin discontinued and oral hypoglycemic agents resumed | No reaction | - | 2 | Sulpha drugs, family history of seasonal allergies |

Table 3. Cases with an immediate insulin hypersensitivity
| Patient | Year | Age | Gender | Allergy to | Insulin Preparations | Reaction | Symptoms | Duration | Treatment | Improvement |
|---------|------|-----|--------|------------|----------------------|----------|----------|----------|-----------|-------------|
| Hasselmann C. (18) | 2013 | 8 | Male | Yes | protamine, NPH, aspart, glargine & lispro | Yes | lispro/Continuous subcutaneous insulin infusion & H1 antagonist | 3 months | | 3 years No |
| Yoshida N. (19) | 2012 | 44 | Female | No | Soluble insulin & lispro | No | aspart & prednisolone (used for acute then chronic graft-versus-host disease) | 12 years | | 7 years No |
| Hasani-Ranjba S. (5) | 2012 | 55 | Female | No | Soluble insulin & NPH | No | glargine & H1 antagonist then aspart | | | 3 months No - Mild intermittent asthma & allergic rhinitis |
| Luyasu S. (20) | 2011 | 59 | Male | No | Multiple insulin preparations | Yes | Glargine | 10 years | | 2 years No - |
| Tuboi M. (21) | 2010 | 43 | Male | No | NPH & protamine | No | No | | | 6 months No - No |
| Wang C. (22) | 2009 | 61 | Male | No | NPH, soluble insulin, premixed human insulin & lispro | No | Insulin discontinued and oral hypoglycemic agents resumed | 17 years | | 1 month No |
| Hara M. (23) | 2009 | 56 | Male | No | NPH | Yes | Glargine, aspart & H1 antagonist | 10 years | | 3 weeks No |
| Caruso C. (24) | 2009 | 65 | Female | No | Soluble insulin | No | Insulin discontinued and oral hypoglycemic agents resumed | | | No |
| Pérez E. (25) | 2009 | 79 | Male | No | detemir | No | glargine & glulisine | 10 years | | No |

Vol. 18, No. 5, October 2019
Published by Tehran University of Medical Sciences (http://ijaai.tums.ac.ir)
| Last Name, First Name | Year | Age | Gender | Years | Insulin Type | Reaction | Treatment | Antigen | Outcome |
|----------------------|------|------|--------|-------|--------------|----------|-----------|--------|---------|
| Mollar-Puchades MA. | 2009 | 70   | Male   | 2     | NPH, Biphasic insulin Aspart, Biphasic insulin lispro, Insulin Lispro Protamine & soluble insulin | No       | No reaction | glargine & glulisine | No penicillin |
| Pföhler C.           | 2008 | 68   | Male   | 2     | Every insulin preparation | Yes       | Ultra-rush desensitization protocol: human insulin then glargine & H1 antagonist | No reaction | 6 months | No |
| Neville KA.          | 2008 | 9    | Male   | 1     | Soluble insulin & NPH | Yes       | Mild symptoms | lispro/continuous subcutaneous insulin infusion & H1 antagonist | 15 months | No |
| Neville KA.          | 2008 | 9    | Male   | 1     | Soluble insulin & NPH | Yes       | Mild symptoms | lispro/continuous subcutaneous insulin infusion & H1 antagonist | 15 months | No |
| Kaya A.              | 2007 | 46   | Female | 2     | Soluble insulin & NPH | Yes       | Anaphylactic reaction | Soluble insulin | Patient had died | No |
| Madero M.F.          | 2006 | 35   | Female | 1     | Recombinant human insulin/glargine | No       | No reaction | lispro | 7 years | No |
| Patient | Year | Age | Gender | Duration | Allergy History | Insulin Types | Therapy | Allergic Reaction | Time | Other Reactions |
|---------|------|-----|--------|----------|----------------|---------------|---------|------------------|------|-----------------|
| Moyes V. | 2006 | 60  | Male   | 11 years | glargine, premixed human insulin, Biphasic insulin lispro \& Biphasic insulin aspart | Yes | lispro/continuous subcutaneous insulin infusion | - | No |
| Katahira M. | 2005 | 56  | Male   | 20 years | Soluble insulin \& premixed human insulin | No | Soluble insulin | - | No |
| Matheu V. | 2005 | 25  | Male   | 3 years | NPH, lispro, soluble insulin \& protamine | Yes | aspart/continuous subcutaneous insulin infusion \& corticosteroids | - | No |
| Kara C. | 2005 | 1   | Female | Neo-natal diabetes | NPH \& soluble insulin | Yes | 1st essay: soluble insulin \& 2nd essay: lispro \& glargine | - | No |
| Adachi A. | 2004 | 66  | Female | 5 year | NPH | No | Human insulin extended zinc suspension | - | No |
| Raubenheimer PJ. | 2004 | 57  | Male   | 10 year | Premixed human insulin \& soluble insulin | Yes | Soluble insulin \& H1 antagonist | - | No |
| Name              | Year | Age | Gender | Duration | Type of Insulin | Concurrent Medications | Skin Reactions | Reaction Duration | Adverse Reactions |
|-------------------|------|-----|--------|----------|-----------------|------------------------|----------------|--------------------|--------------------|
| Baur X.           | 2003 | 2   | Female | 9 year   | NPH, premixed human insulin & protamine | No Insulin discontinued | No | No | No |
| Barranco R.       | 2003 | 62  | Male   | 10 year  | Biphasic insulin lispro | Soluble insulin then lispro & H1 antagonist | Mild local reactions | 6 months | Yes | Extrinsic asthma and urticaria by pyrazolones |
| Yokoyama H.       | 2003 | 64  | Male   | 15 years | Premixed human insulin, crystalline zinc-insulin & protamine | Crystalline zinc-insulin & corticosteroids | No reaction | 6 months | No |
| Rosas Vargas MA.  | 2001 | 13  | Female | 4 years  | Recombinant DNA insulin | Soluble insulin & H1 antagonist | No reaction | 14 months | No |
| Nagai Y.          | 2001 | 81  | Male   | 12 years | Soluble insulin, NPH & protamine | Insulin discontinued and oral hypoglycemic agents resumed | No reaction | > 2 weeks | No |
| Sackey AH.        | 2001 | 6   | Male   | 1 year   | Premixed human insulin | Premixed human insulin & H1 antagonist | Confined with mild local reactions | 2 years | Yes |
| Pánczél P.        | 2000 | 54  | Female | 32 years | NPH (immediate reaction) & protamine (delayed reaction) | Lispro & bedtime sulfonylurea treatment | No reaction | No | Adverse reactions to chromium, pollen, dust, penicillin, acarbose, and metformin |
Insulin Allergy: A Case Report and Literature Review

| Bollinger ME. (42) | 1999 | 19 | Female | 14 years | Soluble insulin & NPH | Yes (4 times) | H1 antagonist & corticosteroids | 1st essay: soluble insulin | 2nd essay: soluble insulin | 3rd: soluble insulin & NPH | 4th: soluble insulin and stopping NPH | 3 months | 3rd essay: similar results | 3 years | Yes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gonzalo MA. (43) | 1998 | 22 | Female | 4 months | Soluble insulin & premixed human insulin | No | Same & H1 antagonist | Methylprednisolone local reaction | Yes | | | | No |
| Nagai T. (44) | 1997 | 63 | Female | 4 months | NPH | Yes | Soluble insulin/continuous subcutaneous insulin infusion | No reaction | | | | 305 days | No | No |

NPH: neutral protamin Hagedorn, ACE: angiotensin-converting enzyme

We reported here an unusual case of allergy to both penicillin and to multiple insulin preparations which were successfully handled by a desensitization protocol using NPH insulin.

REFERENCES

1. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, Goldenberg R, Punthakee Z. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. Can J Diabetes. Avr 2013; 37 Suppl 1:S8-11.
2. Ghazavi M, Johnston GA. Insulin allergy. Clin Dermatol 2011; 29(3):300-5.
3. Waton J. L’allergie à l’insuline : mise au point. Revue Française d’Allergologie 2011; 51(3):336-42.
4. Wheeler B, Taylor B. Successful management of allergy to the insulin excipient metacresol in a child with type 1 diabetes: a case report. J Med Case Rep 2012; 6:263.
5. Hasani-Ranjbar S, Fazlollahi M, Mehri A, Larjani B. Allergy to human insulin and specific immunotherapy with glargine; case report with review of literature. Acta Diabetol 2011; 49(1):69-73.
6. Feinglos M, Jegasothy B. "Insulin" allergy due to zinc. Lancet1979; 313(8108):122-4.
7. Ben Ammar I, Ksouri H, Trabelsi N, Mellouli F, Ben Mami F, Dakhli S, et al. Generalized allergy due to zinc in insulin treated with zinc-free insulin. Acta Diabetol 2010; 49(3):239-41.
8. Kim D, Baraniuk J. Delayed-type hypersensitivity reaction to the meta-cresol component of insulin. Ann Allergy Asthma Immunol 2007; 99(2):194-5.
9. Clerx V, Van Den Keybus C, Kochuyt A, Goossens A. Drug intolerance reaction to insulin therapy caused by metacresol. Contact Dermatitis 2003; 48(3):162-3.
10. Rojas J, Villalobos M, Martinez M, Chávez-Castillo M, Torres W, Mejias J, et al. Successful Management of Insulin Allergy and Autoimmune Polyendocrine Syndrome Type 4 with Desensitization Therapy and Glucocorticoid Treatment: A Case Report and Review of the Literature. Case Reports Immunol 2014; 2014:394754.
11. Bodiger U, Wittrup M. A rational clinical approach to suspected insulin allergy: status after five years and 22 cases. Diabet Med 2005; 22(1):102-6.
12. Mollar-Puchades M, Villanueva I. Insulin glulisine in the treatment of allergy to rapid acting insulin and its rapid acting analogs. Diabetes Res Clin Pract 2009; 83(1):e21-e22.
13. Sola-Gazagnes A, Larger E, Pecquet C, Boitard C. Allergie à l’insuline à l’ère des analogues de l’insuline. Sang Thrombose Vaissieux 2007; 19(8):418-24.
14. Yokoyama H, Fukimoto S, Koyama H, Emoto M,
Kitagawa Y, Nishizawa Y. Insulin allergy; desensitization with crystalline zinc-insulin and steroid tapering. Diabetes Res Clin Prac 2003; 61(3):161-6.

15. Munshi R, Varthakavi P, Belhekar M, Pai S, Tayade P, Dalwadi P. A case of hypersensitivity to soluble and isophane insulins but not to insulin glargine. Indian J Pharmacol 2015;47(2):227-9.

16. Pitrola D, Maclver C, Mallipedhi A, Udiawar M, Price D, Stephens J. Cutaneous allergy to insulin: Could statins and ACE inhibitors play a role? A case report. Diabetes Res Clin Prac 2014; 104(1):e20-2.

17. Jacquier J, Chik C, Senior P. A practical, clinical approach to the assessment and management of suspected insulin allergy. Diabet Med 2013; 30(8):977-85.

18. Hasselmann C, Pecquet C, Bismuth E, Raverdy C, Sola-Gazagnes A, Lobut J, et al. Continuous subcutaneous insulin infusion allows tolerance induction and diabetes treatment in a type 1 diabetic child with insulin allergy. Diabetes Metab 2013; 39(2):174-7.

19. Yoshida N, Okubo M, Ishiguro K, Mori Y. Development of insulin allergy after bone marrow transplantation. Diabet Med 2012; 29(10):1339-41.

20. Luyasu S, Hougardy N, Hasdenteufel F, Jacqueinet S, Weber E, Moneret-Vautrin S, Choc anaphylactique à l’insuline humaine recombinante : suivi d’un protocole d’accoutumance par tests d’activation des basophiles. Rev Med Interne 2011; 32(1):39-42.

21. Tuboi M, Tsuchiya T, Taguchi R, Tanaka Y, Iwasaki Y, Hashimoto K, et al. Insulin allergy whose local/systemic reactions were reduced by desensitization with long-acting insulin analog, Glargine. Nihon Naika Gakkai Zasshi 2010; 9(1):133-5.

22. Wang C, Ding Z, Shu S, Liu Y, Chen Y, Ran X, et al. Severe insulin allergy after percutaneous transluminal coronary angioplasty. Clin Ther 2009;31(3):569-74.

23. Hara M, Izumida Y, Sato N, Ohashi K, Osuga J, Tobe K et al. Successful desensitization by glargine administration in a patient with insulin allergy: A case report. Diabetes Res Clin Prac 2009; 84(3):e48-9.

24. Caruso C, Alonzi C, Gaeta F, Viola M, Romano A. Same-patient allergy to ampicillin and human insulin. Allergy 2009; 64(7):1105-7.

25. Pérez E, González R, Martínez J, Iglesias J, Matheu V. detemir insulin–induced anaphylaxis. Ann Allergy Asthma Immunol 2009; 102(2):174-5.

26. Pföhler C, Müller C, Hasselmann D, Tilgen W. Successful desensitization with human insulin in a patient with an insulin allergy and hypersensitivity to protamine: a case report. J Med Case Reports 2008; 2:283.

27. Neville K, Verge C, Wainstein B, Woodhead H, Ziegler J, Walker J. Insulin allergy desensitization with simultaneous intravenous insulin and continuous subcutaneous insulin infusion. Pediatr Diabetes 2008; 9(4p2):420-2.

28. Kaya A, Gungor K, Karakose S. Severe anaphylactic reaction to human insulin in a diabetic patient. J Diabetes Complications 2007; 21(2):124-7.

29. Madero M, Sastre J, Carnes J, Quirce S, Herrera-Pombo J. IgG4-mediated allergic reaction to glargine insulin. Allergy 2006; 61(8):1022-3.

30. Moyes V, Driver R, Croom A, Mirakian R, Chowdhury T. Insulin allergy in a patient with Type 2 diabetes successfully treated with continuous subcutaneous insulin infusion. Diabet Med 2006; 23(2):204-6.

31. Katahira M, Hara I, Nishizaki T. Insulin allergy decreased by Humulin S (Humulin R) and not by insulin aspart or Actrapid Penfill (Penfill R). Diabet Med 2005; 22(10):1455-7.

32. Mathieu V, Perez E, Hernández M, Díaz E, Darias R, González A, et al. Insulin allergy and resistance successfully treated by desensitisation with Aspart insulin. Clin Mol Allergy 2005; 3(1):16.

33. Kara C, Kutlu A, Evlzeniaoglu O, Bilgili H, Yildirim N. Successful Treatment of Insulin Allergy in a 1-Year-Old Infant With Neonatal Diabetes by Lispro and Glargine Insulin. Diabetes Care 2005; 28(4):983-4.

34. Adachi A, Fukunaga A, Horikawa T. A case of human insulin allergy induced by short-acting and intermediate-acting insulin but not by long-acting insulin. Int J Dermatol 2004; 43(8):597-9.

35. Raubenheimer P, Levitt N. A case of generalised allergic reaction to human insulin. J Endocrinol Metab Diabetes S Afr 2004; 9(1):18-20.

36. Baur X, Bossert J, Koops F. IgE-mediated allergy to recombinant human insulin in a diabetic. Allergy 2003; 58(7):676-8.

37. Barranco R, Herrero T, Tornero P, Barrio M, Frutos C, Rodriguez A, et al. Systemic allergic reaction by a human insulin analog. Allergy 2003; 58(6):536-7.

38. Rosas Vargas M, Alvarez Amador M, Alvarez Amador L, del Rio Navarro B, Avila Castanón L, Sienra Monge J. Desensitization to human recombinant DNA insulin in an adolescent with insulin-dependent diabetes mellitus. Rev Alerg Mex 2001; 48(5):129-32.

39. Nagai Y, Mori T, Abe T, Nomura G. Immediate-Type allergy against human insulin associated with marked eosinophilia in type 2 diabetic patient. Endocr J 2001; 48(3):311-6.
40. Sackey A. Drug points: Recurrent generalised urticaria at insulin injection sites. BMJ 2000; 321(7274):1449.
41. Pánczel P, Hosszúfalusi N, Horváth M, Horváth A. Advantage of insulin lispro in suspected insulin allergy. Allergy 2000; 55(4):409-10.
42. Bollinger M, Hamilton R, Wood R. Protamine allergy as a complication of insulin hypersensitivity: A case report. J Allergy Clin Immunol 1999; 104(2):462-5.
43. Gonzalo M, Argila D, Revenga F, Garcia J, Diaz J, Morales F. Cutaneous allergy to human (recombinant DNA) insulin. Allergy 1998; 53(1):106-7.
44. Nagai T, Nagai Y, Tomizawa T, Mori M. Immediate-type human insulin allergy successfully treated by continuous subcutaneous insulin infusion. Intern Med 1997; 36(8):575-8.
45. Akinci B, Yener S, Bayraktar F, Yesil S. Allergic reactions to human insulin: a review of current knowledge and treatment options. Endocrine 2009; 37(1):33-9.